EA202092955A1 - Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза - Google Patents
Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброзаInfo
- Publication number
- EA202092955A1 EA202092955A1 EA202092955A EA202092955A EA202092955A1 EA 202092955 A1 EA202092955 A1 EA 202092955A1 EA 202092955 A EA202092955 A EA 202092955A EA 202092955 A EA202092955 A EA 202092955A EA 202092955 A1 EA202092955 A1 EA 202092955A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alcoxy
- fibrosis
- antagonists
- treatment
- application
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 title 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 title 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018065016 | 2018-06-07 | ||
| PCT/EP2019/064690 WO2019234115A1 (en) | 2018-06-07 | 2019-06-05 | Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092955A1 true EA202092955A1 (ru) | 2021-04-08 |
Family
ID=66912779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092955A EA202092955A1 (ru) | 2018-06-07 | 2019-06-05 | Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12344597B2 (enExample) |
| EP (1) | EP3802517B1 (enExample) |
| JP (1) | JP7386183B2 (enExample) |
| KR (1) | KR102826034B1 (enExample) |
| CN (1) | CN112236424B (enExample) |
| AU (1) | AU2019282274A1 (enExample) |
| BR (1) | BR112020024879A2 (enExample) |
| CA (1) | CA3102683A1 (enExample) |
| DK (1) | DK3802517T3 (enExample) |
| EA (1) | EA202092955A1 (enExample) |
| ES (1) | ES2940695T3 (enExample) |
| FI (1) | FI3802517T3 (enExample) |
| HR (1) | HRP20230243T1 (enExample) |
| HU (1) | HUE061559T2 (enExample) |
| LT (1) | LT3802517T (enExample) |
| MX (1) | MX2020013291A (enExample) |
| PL (1) | PL3802517T3 (enExample) |
| PT (1) | PT3802517T (enExample) |
| RS (1) | RS63990B1 (enExample) |
| SI (1) | SI3802517T1 (enExample) |
| TW (1) | TW202016090A (enExample) |
| WO (1) | WO2019234115A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023214119A1 (en) | 2022-05-05 | 2023-11-09 | Equinorm Ltd | Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of cns disorders |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119162A1 (es) * | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| WO2021110805A1 (en) * | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| WO2025169931A1 (ja) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | カルボキサミド化合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130088C (enExample) | 1960-03-14 | |||
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AU7961300A (en) | 1999-10-29 | 2001-05-14 | Yamanouchi Pharmaceutical Co., Ltd. | Kainic acid neurocytotoxicity inhibitors |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| WO2005037269A1 (ja) | 2003-10-21 | 2005-04-28 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ピペリジン誘導体 |
| EP1687296A1 (en) | 2003-11-18 | 2006-08-09 | Warner-Lambert Company LLC | Antibacterial aminoquinazolidinedione derivatives |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| TWI377198B (en) | 2005-08-24 | 2012-11-21 | Eisai R&D Man Co Ltd | Novel pyridine derivatives and pyrimidine derivatives (3) |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| WO2008115281A2 (en) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| AU2008311971A1 (en) | 2007-10-18 | 2009-04-23 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| EP2297153B1 (en) | 2008-04-21 | 2015-05-27 | Lexicon Pharmaceuticals, Inc. | Limk2 inhibitors, compositions comprising them, and methods of their use |
| AU2009243756B2 (en) | 2008-05-05 | 2013-06-27 | Sanofi-Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| BRPI0918971A2 (pt) | 2008-08-26 | 2015-12-01 | Boehringer Ingelheim Int | tienopirimidinas para composições farmacêuticas |
| JP5708936B2 (ja) | 2009-09-25 | 2015-04-30 | アステラス製薬株式会社 | 置換アミド化合物 |
| ES2682303T3 (es) | 2010-08-05 | 2018-09-19 | Zoetis Services Llc | Derivados de isoxazolina como agentes antiparasitarios |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| CN107721940A (zh) | 2010-12-07 | 2018-02-23 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| PT2683723T (pt) | 2011-03-10 | 2016-08-05 | Zoetis Services Llc | Derivados espirocíclicos de isoxazolina como agentes antiparasitários |
| JP2015506349A (ja) | 2011-12-21 | 2015-03-02 | アルデリックス， インコーポレイテッド | 非全身性ｔｇｒ５アゴニスト |
| WO2014079805A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| TW201444820A (zh) * | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
-
2019
- 2019-06-05 HU HUE19731163A patent/HUE061559T2/hu unknown
- 2019-06-05 CN CN201980036967.6A patent/CN112236424B/zh active Active
- 2019-06-05 HR HRP20230243TT patent/HRP20230243T1/hr unknown
- 2019-06-05 PL PL19731163.2T patent/PL3802517T3/pl unknown
- 2019-06-05 PT PT197311632T patent/PT3802517T/pt unknown
- 2019-06-05 EP EP19731163.2A patent/EP3802517B1/en active Active
- 2019-06-05 TW TW108119605A patent/TW202016090A/zh unknown
- 2019-06-05 FI FIEP19731163.2T patent/FI3802517T3/fi active
- 2019-06-05 ES ES19731163T patent/ES2940695T3/es active Active
- 2019-06-05 SI SI201930472T patent/SI3802517T1/sl unknown
- 2019-06-05 US US16/972,878 patent/US12344597B2/en active Active
- 2019-06-05 RS RS20230148A patent/RS63990B1/sr unknown
- 2019-06-05 DK DK19731163.2T patent/DK3802517T3/da active
- 2019-06-05 JP JP2020567808A patent/JP7386183B2/ja active Active
- 2019-06-05 WO PCT/EP2019/064690 patent/WO2019234115A1/en not_active Ceased
- 2019-06-05 MX MX2020013291A patent/MX2020013291A/es unknown
- 2019-06-05 LT LTEPPCT/EP2019/064690T patent/LT3802517T/lt unknown
- 2019-06-05 AU AU2019282274A patent/AU2019282274A1/en not_active Abandoned
- 2019-06-05 EA EA202092955A patent/EA202092955A1/ru unknown
- 2019-06-05 KR KR1020217000125A patent/KR102826034B1/ko active Active
- 2019-06-05 BR BR112020024879-7A patent/BR112020024879A2/pt not_active IP Right Cessation
- 2019-06-05 CA CA3102683A patent/CA3102683A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023214119A1 (en) | 2022-05-05 | 2023-11-09 | Equinorm Ltd | Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of cns disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102826034B1 (ko) | 2025-06-27 |
| KR20210018900A (ko) | 2021-02-18 |
| CN112236424A (zh) | 2021-01-15 |
| BR112020024879A2 (pt) | 2021-03-09 |
| CA3102683A1 (en) | 2019-12-12 |
| WO2019234115A1 (en) | 2019-12-12 |
| JP7386183B2 (ja) | 2023-11-24 |
| AU2019282274A1 (en) | 2021-01-28 |
| FI3802517T3 (fi) | 2023-03-23 |
| PL3802517T3 (pl) | 2023-05-22 |
| US12344597B2 (en) | 2025-07-01 |
| US20210246116A1 (en) | 2021-08-12 |
| TW202016090A (zh) | 2020-05-01 |
| CN112236424B (zh) | 2024-03-15 |
| LT3802517T (lt) | 2023-03-10 |
| EP3802517B1 (en) | 2022-12-21 |
| MX2020013291A (es) | 2021-04-29 |
| ES2940695T3 (es) | 2023-05-10 |
| RS63990B1 (sr) | 2023-03-31 |
| HRP20230243T1 (hr) | 2023-04-14 |
| JP2021527046A (ja) | 2021-10-11 |
| HUE061559T2 (hu) | 2023-07-28 |
| EP3802517A1 (en) | 2021-04-14 |
| PT3802517T (pt) | 2023-03-20 |
| DK3802517T3 (da) | 2023-03-13 |
| SI3802517T1 (sl) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500188A1 (en) | Piperidine cxcr7 receptor modulators | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| EA201992679A1 (ru) | N-замещенные индольные производные | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MX375978B (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2. | |
| PH12022550338A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| MX2021004940A (es) | Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos. | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| JOP20190183B1 (ar) | معدِلات مستقبلات الاستروجين | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| MX2020013291A (es) | Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis. | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| PH12021553178A1 (en) | Pyridin-3-yl derivatives | |
| EA202090995A1 (ru) | Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1 | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| EA201991045A1 (ru) | Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| ZA202203108B (en) | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections | |
| EA201992296A1 (ru) | Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета | |
| TN2018000175A1 (en) | Indane derivatives as mglur7 modulators | |
| EA201891027A1 (ru) | Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение | |
| MX2021004471A (es) | Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1. | |
| TH1901007033A (th) | อนุพันธ์ของอินโดลที่ถูกแทนที่แบบ n |